Buy SARMS UK
Selective Androgen Receptor Modulators
Selective Androgen Receptor Modulators (SARMs UK)
Our range of Selective Androgen Receptor Modulators (SARMs) represent a groundbreaking class of compounds engineered to selectively target androgen receptors (AR) in muscle and bone tissue. Designed to minimize interaction with androgen receptors in other tissues, SARMs aim to provide the anabolic benefits of traditional anabolic agents while reducing unwanted side effects. SARMs have become an invaluable resource in research related to muscle wasting, osteoporosis, and other conditions requiring tissue-specific androgen receptor modulation.
Product Features and Specifications
- Chemical Nature: Non-steroidal ligands engineered for selective binding to androgen receptors.
- Target Pathways: SARMs induce tissue-selective anabolic effects by modulating gene activation and transcription, favoring pathways that enhance muscle and bone growth while reducing androgenic activity.
- Available Forms: Pure crystalline powders, liquid solutions, or controlled-release pellets, all tailored for research applications.
- Purity: ≥99% purity verified by HPLC analysis.
- Solubility: Soluble in DMSO, ethanol, and aqueous solutions under pH-controlled conditions.
- Stability: Chemically stable when stored at -20°C in a dry, light-protected environment.
Â
Material Safety Data for SARMs
SARMs Mechanism of Action
SARMs are extensively utilized in preclinical and translational research for various therapeutic applications:
Muscle Wasting Disorders:
SARMs have demonstrated potential in mitigating muscle atrophy associated with cachexia, sarcopenia, and chronic diseases. Their anabolic effects have been shown to increase lean muscle mass without the significant adverse effects seen with steroidal compounds.Osteoporosis Research:
By promoting bone mineral density and reducing bone resorption, SARMs offer a promising alternative for investigating osteoporosis therapies and fracture prevention strategies.Metabolic Studies:
SARMs can enhance metabolic rate and reduce fat mass while preserving lean muscle, making them valuable for studying obesity and metabolic syndromes.Anti-Aging and Endurance Studies:
Research has also highlighted their role in improving physical performance, endurance, and recovery, relevant to aging-related muscle and bone deterioration.
Remember to check out our SARMs information
Research Insights
Clinical and preclinical studies underline the potential of SARMs to revolutionize therapeutic approaches to anabolic disorders:
Muscle Mass Enhancement:
Trials demonstrate that SARMs like Ostarine (MK-2866) and LGD-4033 significantly increase lean body mass and strength in both animal and human models, with fewer side effects compared to anabolic steroids. (PubMed Link)Bone Density Improvement:
SARMs have shown efficacy in increasing bone density, reducing fractures, and promoting osteoblast activity, making them ideal candidates for osteoporosis research. (PubMed Link)Fat Loss and Metabolism:
Studies indicate SARMs influence fat metabolism by upregulating genes responsible for lipolysis while preserving muscle mass. (PubMed Link)Reduced Adverse Effects:
Unlike traditional anabolic agents, SARMs demonstrate a reduced impact on prostate size and androgen-sensitive tissues. (PubMed Link)
Safety and Handling
- Intended Use: SARMs are for research use only and not for human or veterinary applications.
- Handling: Researchers must use personal protective equipment (PPE) and handle under appropriate laboratory conditions.
- Storage Recommendations: Ensure products are stored at -20°C, protected from light and moisture to maintain stability and efficacy.
- Regulatory Compliance: SARMs are supplied strictly for laboratory research. Researchers are responsible for adhering to all applicable local and international regulations.
Packaging Options
- Standard Quantities: Available in 10 mg, 25 mg, and 50 mg vials or pellet forms.
- Custom Configurations: Bulk orders and specific formulations can be tailored to meet unique research requirements.
Technical Support
We offers expert technical support for SARMs, including detailed protocols, analytical guidance, and troubleshooting. Our team is available to help you optimize your research outcomes with reliable and reproducible data.
SARM Profiles
Ostarine SARM
| Detail | Link |
|---|---|
| PubChem CID (11326715) | PubChem |
| DrugBank (DB12078) | DrugBank |
| ChemSpider (9501667) | ChemSpider |
| UNII (O3571H3R8N) | UNII |
| KEGG (D10221) | KEGG |
| ChEMBL (ChEMBL1738889) | ChEMBL |
| PDB ligand (RLJ) | PDBe, RCSB PDB |
| CompTox Dashboard (DTXSID30233006) | EPA CompTox |
Ostarine, also known by its developmental code MK-2866, represents a prototypical member of the selective androgen receptor modulators (SARMs) class of compounds.Â
Engineered to selectively target androgen receptors in skeletal muscle and bone, ostarine stands at the forefront of an emerging class of molecules designed with the intention of achieving the beneficial effects of androgens, such as testosterone, while minimizing untoward effects on other tissues.
The molecular design of ostarine allows it to preferentially induce anabolic activity in muscle and bone. This specific activity profile is derived from its ability to bind to the androgen receptors in these tissues more effectively than in others, such as the prostate, liver, and brain.
 Consequently, ostarine has been the subject of considerable interest for its potential applications in treating a range of musculoskeletal conditions, including muscle wasting diseases associated with cancer, age, and other chronic conditions, as well as osteoporosis, where its ability to stimulate bone formation could prove beneficial.
Â
Â
Ostarine Clinical Studies
A Phase 2b clinical trial by Veru Inc. explores the use of enobosarm (ostarine) in combination with GLP-1 receptor agonists for the treatment of muscle loss in sarcopenic obese or overweight elderly patients. This study aims to validate enobosarm’s ability to preserve muscle and physical function while enhancing fat loss​ (globenewswire)​.
Another study presented by GTx at the Endocrine Society Annual Meeting evaluated the effects of ostarine in patients with cancer cachexia. The trial demonstrated significant improvements in lean body mass and muscle performance in the patients treated with ostarine compared to baseline​ (fiercebiotech)​.
GTx also conducted a Phase II clinical trial that was discussed in a press release from Business Wire. This study focused on cancer cachexia in patients suffering from various types of cancer, and found that ostarine treatment led to significant increases in lean body mass​ (businesswire)​.
The results from multiple clinical trials involving ostarine were summarized in a GlobeNewswire press release, indicating dose-dependent increases in muscle mass and reductions in fat mass across different patient groups, including elderly and cancer patients​ (globenewswire)​.
A further Phase 2b clinical trial by Veru Inc., as described on Finance Yahoo, aims to start in April 2024. This trial will investigate the effectiveness of enobosarm in preventing muscle loss and augmenting fat loss in elderly patients on GLP-1 RA therapy​ (finance.yahoo)​.
SARMs Clinical Safety
SARM Side Effect Profile
Cardiovascular Risks: Reduction in high-density lipoprotein (HDL) cholesterol, potentially elevating cardiovascular risk.
Hepatotoxicity: Increases in liver enzymes indicating potential liver stress or damage, which may be reversible with cessation of usage.
Endocrine Effects: Suppression of endogenous testosterone production leading to symptoms such as fatigue, mood disturbances, and decreased libido.
Masculinizing Effects in Women: Potential masculinizing effects such as increased body hair and vocal changes, though less pronounced than with anabolic steroids.
Psychological Impact: Mood swings and other changes in mental health.